Radiation Therapy

The radiation therapy channel covers all aspects of radiation oncology technology. Radiation therapy includes linear accelerators (LINAC), proton therapy, brachytherapy, image guided radiation therapy (IGRT), focused ultrasound, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), treatment planning systems and tomotherapy.

A study involving researchers at Karolinska Institutet and Gothenburg University in Sweden has found that low levels of a protein called PDGFRb are associated with particularly good results of radiotherapy in women with early-stage breast cancer.
News | Radiation Therapy | May 11, 2021
May 11, 2021 —A study involving researchers at Karolinska Institutet and Gothenburg University in Sweden has found that...
News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe Alzheimer's disease showed remarkable improvements in behavior and...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diagnostic procedures single-photon emission computed tomography (...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer...
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breast cancer can pave the way for a notable higher success rate,...
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine...
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI...
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in artificial intelligence (AI) for cancer care, announced it received the U.S....
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanced...
Boston Scientific Corporation announced positive data from the TARGET study of the TheraSphere Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of millions of microscopic glass beads containing radioactive yttrium (Y-90) – during a late-breaking clinical trial presentation at the annual scientific meeting for the Society of Interventional Radiology (SIR).
News | Interventional Radiology | March 25, 2021
March 25, 2021 — Boston Scientific Corporation announced positive data from the TARGET study of the TheraSphere Y-90 ...
Sun Nuclear Corporation announced that Australia's Northern Sydney Cancer Centre (NSCC) is now a reference site for the SunCHECK Quality Management Platform.
News | Radiation Therapy | March 25, 2021
March 25, 2021 — Sun Nuclear Corporation announced that Australia's Northern Sydney Cancer Centre (NSCC) is now a...
A new study led by Ivan Martinez—associate professor in the WVU School of Medicine and Cancer Institute—found a link between a family of RNAs, the Y chromosome, and radiation sensitivity in male lung-cancer patients
News | Radiation Therapy | March 23, 2021
March 23, 2021 — The science behind the COVID-19 vaccine has the potential to do more than prevent cases of COVID-19...
Cancer tissue being bombarded by targeted alpha particles. The generator developed by Los Alamos National Laboratory holds uranium-230, which decays to thorium-226. Further decay produces short-lived daughter isotopes, emitting four more alpha particles resulting in a very high combined radiation dose to destroy cancer cells.

Cancer tissue being bombarded by targeted alpha particles. The generator developed by Los Alamos National Laboratory holds uranium-230, which decays to thorium-226. Further decay produces short-lived daughter isotopes, emitting four more alpha particles resulting in a very high combined radiation dose to destroy cancer cells.

News | Radiation Therapy | March 23, 2021
March 23, 2021 — Improved options for cancer treatment are on the way, thanks to a new system developed at Los Alamos...
Radiofrequency ablation for the palliative treatment of osseous metastases reduces pain and improves quality of life

Radiofrequency ablation for the palliative treatment of osseous metastases reduces pain and improves quality of life.

News | Interventional Radiology | March 19, 2021
March 19, 2021 — A minimally invasive treatment for patients whose cancer has spread to their bones provides quick and...
Boston Scientific's TheraSphere Y-90 Glass Microspheres enable selective internal radiation therapy (SIRT), or radioembolization, for hepatocellular carcinoma. This treats liver cancer with low toxicity using millions of microscopic glass beads containing radioactive yttrium (Y-90), delivered directly to liver tumors via catheter. The result in minimal radiation exposure to surrounding healthy tissue.

Boston Scientific's TheraSphere Y-90 Glass Microspheres enable selective internal radiation therapy (SIRT), or radioembolization, for hepatocellular carcinoma. This treats liver cancer with low toxicity using millions of microscopic glass beads containing radioactive yttrium (Y-90), delivered directly to liver tumors via catheter. The result in minimal radiation exposure to surrounding healthy tissue.

News | Radiation Therapy | March 18, 2021
March 18, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's TheraSphere Y-90 Glass...
WVU Rockefeller Neuroscience Institute staff prepare a patient for a first-in-the-world clinical trial to investigate the use of focused ultrasound technology to treat opioid use disorder. (WVU Photo/Brian Persinger)

WVU Rockefeller Neuroscience Institute staff prepare a patient for a first-in-the-world clinical trial to investigate the use of focused ultrasound technology to treat opioid use disorder. (WVU Photo/Brian Persinger)

News | Focused Ultrasound Therapy | March 17, 2021
March 17, 2021 — On the heels of the country’s deadliest year for drug overdoses, the West Virginia University...
Stefan Vilsmeier Brainlab announced the acquisition of Mint Medical GmbH, a Heidelberg-based company that develops image reading and reporting software for clinical routine and research

Stefan Vilsmeier, President and CEO, Brainlab

News | Treatment Planning | March 10, 2021
March 10, 2021 — Brainlab announced the acquisition of Mint Medical GmbH, a Heidelberg-based company that develops...
Methodology for evaluation of tumor cell density (TCD) and allocation of radiotherapy response categories. (A) Virtual graticule of approximately 300 points applied to tumor area on a digital H&E section. (B) Demonstration of TCD point scoring. (C) Box and whisker plot to show the relationship between ΔTCD and American Joint Committee on Cancer (AJCC) Tumour Regression Grade System (TRG). (D, E) Allocation of three radiotherapy response groups according to change in TCD (ΔTCD) for short-course radiotherapy

Methodology for evaluation of tumor cell density (TCD) and allocation of radiotherapy response categories. (A) Virtual graticule of approximately 300 points applied to tumor area on a digital H&E section. (B) Demonstration of TCD point scoring. (C) Box and whisker plot to show the relationship between ΔTCD and American Joint Committee on Cancer (AJCC) Tumour Regression Grade System (TRG). (D, E) Allocation of three radiotherapy response groups according to change in TCD (ΔTCD) for short-course radiotherapy (SCRT) (D) and long-course chemoradiotherapy (LCRT) (E). The Kruskall-Wallis test was used for statistical comparisons. Image courtesy of BMJ

News | Radiation Oncology | March 09, 2021
March 9, 2021 — Cancers that are resistant to radiotherapy could be rendered susceptible through treatment with...
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy.  The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Feature | Treatment Planning | March 05, 2021 | By Melinda Taschetta-Millane
The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and...